France (FR)

Time 2EVOLVE: predicting efficacy of engineered T-cells - how far is the bench from the bedside? (2022) Guedan S, Luu M, Ammar D, Barbao P, Bonini C, Bousso P, Buchholz CJ, et al. Journal article, Review article Time to evolve: predicting engineered T cell-associated toxicity with next-generation models (2022) Donnadieu E, Luu M, Alb M, Anliker B, Arcangeli S, Bonini C, De Angelis B, et al. Journal article, Review article LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma (2022) Mateos MV, Weisel K, De Stefano V, Goldschmidt H, Delforge M, Mohty M, Cavo M, et al. Journal article Allogeneic hematopoietic stem cell transplantation for adult HLH: a retrospective study by the chronic malignancies and inborn errors working parties of EBMT (2022) Machowicz R, Suarez F, Wiktor-Jedrzejczak W, Eikema DJ, De Wreede LC, Blok HJ, Isaksson C, et al. Journal article Carotid Ultrasound Boundary Study (CUBS): Technical considerations on an open multi-center analysis of computerized measurement systems for intima-media thickness measurement on common carotid artery longitudinal B-mode ultrasound scans (2022) Meiburger KM, Marzola F, Zahnd G, Faita F, Loizou CP, Laine N, Carvalho C, et al. Journal article Atomistic aspects of load transfer and fracture in CNT-reinforced aluminium (2022) Nasiri S, Wang K, Yang M, Guénolé J, Li Q, Zaiser M Journal article PRECLINICAL EFFICACY OF DIRECT AMPK ACTIVATION WITH A NOVEL SMALL MOLECULE-PXL770-FOR THE TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (2022) Dagorn PG, Buchholz B, Bange H, Blockken L, Moller DE, Hallakou-Bozec S Conference contribution Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant treatment (2022) Marme F, Hanusch C, Furlanetto J, Morris P, Link T, Denkert C, Fasching P, et al. Conference contribution Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: Phase IIIb LUCY final analysis (2022) Balmana J, Fasching P, Delaloge S, Park YH, Eisen A, Bourgeois H, Kemp Z, et al. Conference contribution The eROSITA Final Equatorial Depth Survey (eFEDS): X-ray catalogue (2022) Brunner H, Liu T, Lamer G, Georgakakis A, Merloni A, Brusa M, Bulbul E, et al. Journal article